Serum levels of miR-126 and miR-223 and outcomes in chronic kidney disease patients

Ophélie Fourdinier; Eva Schepers; Valérie Metzinger-Le Meuth; Griet Glorieux; Sophie Liabeuf; Francis Verbeke; Raymond Vanholder; Benjamin Brigant; Anneleen Pletinck; Momar Diouf; Stéphane Burtey; Gabriel Choukroun; Ziad A. Massy; Laurent Metzinger; Angel Argiles; Joachim Beige; Philippe Brunet; Gerald Cohen; Omar Abou Deif; Pieter Evenepoel; Danilo Fliser; Ivo Fridolin; Andreas Gmerek; Joachim Jankowski; Vera Jankowski; Roos Masereeuw; Harald Mischak; Alberto Ortiz; Alessandra Perna; Juan Mariano Rodriguez-Portillo; Joost Schanstra; Goce Spasovski; Dimitrios Stamatialis; Sonja Steppan; Markus Storr; Bernd G. Stegmayr; Peter Stenvinkel; Paul J. Thornalley; Andrej Wiecek; on behalf of the European Uremic Toxin Work Group-EUTox

doi:10.1038/s41598-019-41101-8

Serum levels of miR-126 and miR-223 and outcomes in chronic kidney disease patients

Ophélie Fourdinier, Eva Schepers, Valérie Metzinger-Le Meuth, Griet Glorieux, Sophie Liabeuf, Francis Verbeke, Raymond Vanholder, Benjamin Brigant, Anneleen Pletinck, Momar Diouf, Stéphane Burtey, Gabriel Choukroun, Ziad A. Massy, Laurent Metzinger^* (Corresponding Author), Angel Argiles, Joachim Beige, Philippe Brunet, Gerald Cohen, Omar Abou Deif, Pieter EvenepoelDanilo Fliser, Ivo Fridolin, Andreas Gmerek, Joachim Jankowski, Vera Jankowski, Roos Masereeuw, Harald Mischak, Alberto Ortiz, Alessandra Perna, Juan Mariano Rodriguez-Portillo, Joost Schanstra, Goce Spasovski, Dimitrios Stamatialis, Sonja Steppan, Markus Storr, Bernd G. Stegmayr, Peter Stenvinkel, Paul J. Thornalley, Andrej Wiecek, on behalf of the European Uremic Toxin Work Group-EUTox

^*Corresponding author for this work

Biomaterials Science and Technology

Research output: Contribution to journal › Article › Academic › peer-review

54 Citations (Scopus)

120 Downloads (Pure)

Abstract

Several microRNAs (miRNAs) have been linked to chronic kidney disease (CKD) mortality, cardiovascular (CV) complications and kidney disease progression. However, their association with clinical outcomes remains poorly evaluated. We used real-time qPCR to measure serum levels of miR-126 and miR-223 in a large cohort of 601 CKD patients (CKD stage G1 to G5 patients or on renal replacement therapy – CKD G5D) from Ghent University Hospital and 31 healthy controls. All-cause mortality and cardiovascular and renal events were registered as endpoints over a 6 year follow-up period. miR-126 levels were significantly lower from CKD stage G2 on, compared to controls. The serum levels of miR-223 were significantly lower from CKD stage G3B on. When considering overall mortality, patients with levels of either miR-126 or miR-223 below the median had a lower survival rate. Similar results were observed for CV and renal events. The observed link between the two miRNAs’ seric levels and mortality, cardiovascular events or renal events in CKD appears to depend on eGFR. However, this does not preclude their potential role in the pathophysiology of CKD. In conclusion, CKD is associated with a decrease in circulating miR-223 and miR-126 levels.

Original language	English
Article number	4477
Journal	Scientific reports
Volume	9
Issue number	1
DOIs	https://doi.org/10.1038/s41598-019-41101-8
Publication status	Published - 14 Mar 2019

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/s41598-019-41101-8Licence: CC BY

serumFinal published version, 1.95 MBLicence: CC BY

Cite this

Fourdinier, O., Schepers, E., Metzinger-Le Meuth, V., Glorieux, G., Liabeuf, S., Verbeke, F., Vanholder, R., Brigant, B., Pletinck, A., Diouf, M., Burtey, S., Choukroun, G., Massy, Z. A., Metzinger, L., Argiles, A., Beige, J., Brunet, P., Cohen, G., Deif, O. A., ... on behalf of the European Uremic Toxin Work Group-EUTox (2019). Serum levels of miR-126 and miR-223 and outcomes in chronic kidney disease patients. Scientific reports, 9(1), Article 4477. https://doi.org/10.1038/s41598-019-41101-8

@article{962036bb173e46cf9cad4e333accbbcd,

title = "Serum levels of miR-126 and miR-223 and outcomes in chronic kidney disease patients",

abstract = "Several microRNAs (miRNAs) have been linked to chronic kidney disease (CKD) mortality, cardiovascular (CV) complications and kidney disease progression. However, their association with clinical outcomes remains poorly evaluated. We used real-time qPCR to measure serum levels of miR-126 and miR-223 in a large cohort of 601 CKD patients (CKD stage G1 to G5 patients or on renal replacement therapy – CKD G5D) from Ghent University Hospital and 31 healthy controls. All-cause mortality and cardiovascular and renal events were registered as endpoints over a 6 year follow-up period. miR-126 levels were significantly lower from CKD stage G2 on, compared to controls. The serum levels of miR-223 were significantly lower from CKD stage G3B on. When considering overall mortality, patients with levels of either miR-126 or miR-223 below the median had a lower survival rate. Similar results were observed for CV and renal events. The observed link between the two miRNAs{\textquoteright} seric levels and mortality, cardiovascular events or renal events in CKD appears to depend on eGFR. However, this does not preclude their potential role in the pathophysiology of CKD. In conclusion, CKD is associated with a decrease in circulating miR-223 and miR-126 levels.",

author = "Oph{\'e}lie Fourdinier and Eva Schepers and {Metzinger-Le Meuth}, Val{\'e}rie and Griet Glorieux and Sophie Liabeuf and Francis Verbeke and Raymond Vanholder and Benjamin Brigant and Anneleen Pletinck and Momar Diouf and St{\'e}phane Burtey and Gabriel Choukroun and Massy, {Ziad A.} and Laurent Metzinger and Angel Argiles and Joachim Beige and Philippe Brunet and Gerald Cohen and Deif, {Omar Abou} and Pieter Evenepoel and Danilo Fliser and Ivo Fridolin and Andreas Gmerek and Joachim Jankowski and Vera Jankowski and Roos Masereeuw and Harald Mischak and Alberto Ortiz and Alessandra Perna and Rodriguez-Portillo, {Juan Mariano} and Joost Schanstra and Goce Spasovski and Dimitrios Stamatialis and Sonja Steppan and Markus Storr and Stegmayr, {Bernd G.} and Peter Stenvinkel and Thornalley, {Paul J.} and Andrej Wiecek and {on behalf of the European Uremic Toxin Work Group-EUTox}",

year = "2019",

month = mar,

day = "14",

doi = "10.1038/s41598-019-41101-8",

language = "English",

volume = "9",

journal = "Scientific reports",

issn = "2045-2322",

publisher = "Nature Publishing Group",

number = "1",

}

Fourdinier, O, Schepers, E, Metzinger-Le Meuth, V, Glorieux, G, Liabeuf, S, Verbeke, F, Vanholder, R, Brigant, B, Pletinck, A, Diouf, M, Burtey, S, Choukroun, G, Massy, ZA, Metzinger, L, Argiles, A, Beige, J, Brunet, P, Cohen, G, Deif, OA, Evenepoel, P, Fliser, D, Fridolin, I, Gmerek, A, Jankowski, J, Jankowski, V, Masereeuw, R, Mischak, H, Ortiz, A, Perna, A, Rodriguez-Portillo, JM, Schanstra, J, Spasovski, G, Stamatialis, D, Steppan, S, Storr, M, Stegmayr, BG, Stenvinkel, P, Thornalley, PJ, Wiecek, A & on behalf of the European Uremic Toxin Work Group-EUTox 2019, 'Serum levels of miR-126 and miR-223 and outcomes in chronic kidney disease patients', Scientific reports, vol. 9, no. 1, 4477. https://doi.org/10.1038/s41598-019-41101-8

TY - JOUR

T1 - Serum levels of miR-126 and miR-223 and outcomes in chronic kidney disease patients

AU - Fourdinier, Ophélie

AU - Schepers, Eva

AU - Metzinger-Le Meuth, Valérie

AU - Glorieux, Griet

AU - Liabeuf, Sophie

AU - Verbeke, Francis

AU - Vanholder, Raymond

AU - Brigant, Benjamin

AU - Pletinck, Anneleen

AU - Diouf, Momar

AU - Burtey, Stéphane

AU - Choukroun, Gabriel

AU - Massy, Ziad A.

AU - Metzinger, Laurent

AU - Argiles, Angel

AU - Beige, Joachim

AU - Brunet, Philippe

AU - Cohen, Gerald

AU - Deif, Omar Abou

AU - Evenepoel, Pieter

AU - Fliser, Danilo

AU - Fridolin, Ivo

AU - Gmerek, Andreas

AU - Jankowski, Joachim

AU - Jankowski, Vera

AU - Masereeuw, Roos

AU - Mischak, Harald

AU - Ortiz, Alberto

AU - Perna, Alessandra

AU - Rodriguez-Portillo, Juan Mariano

AU - Schanstra, Joost

AU - Spasovski, Goce

AU - Stamatialis, Dimitrios

AU - Steppan, Sonja

AU - Storr, Markus

AU - Stegmayr, Bernd G.

AU - Stenvinkel, Peter

AU - Thornalley, Paul J.

AU - Wiecek, Andrej

AU - on behalf of the European Uremic Toxin Work Group-EUTox

PY - 2019/3/14

Y1 - 2019/3/14

N2 - Several microRNAs (miRNAs) have been linked to chronic kidney disease (CKD) mortality, cardiovascular (CV) complications and kidney disease progression. However, their association with clinical outcomes remains poorly evaluated. We used real-time qPCR to measure serum levels of miR-126 and miR-223 in a large cohort of 601 CKD patients (CKD stage G1 to G5 patients or on renal replacement therapy – CKD G5D) from Ghent University Hospital and 31 healthy controls. All-cause mortality and cardiovascular and renal events were registered as endpoints over a 6 year follow-up period. miR-126 levels were significantly lower from CKD stage G2 on, compared to controls. The serum levels of miR-223 were significantly lower from CKD stage G3B on. When considering overall mortality, patients with levels of either miR-126 or miR-223 below the median had a lower survival rate. Similar results were observed for CV and renal events. The observed link between the two miRNAs’ seric levels and mortality, cardiovascular events or renal events in CKD appears to depend on eGFR. However, this does not preclude their potential role in the pathophysiology of CKD. In conclusion, CKD is associated with a decrease in circulating miR-223 and miR-126 levels.

AB - Several microRNAs (miRNAs) have been linked to chronic kidney disease (CKD) mortality, cardiovascular (CV) complications and kidney disease progression. However, their association with clinical outcomes remains poorly evaluated. We used real-time qPCR to measure serum levels of miR-126 and miR-223 in a large cohort of 601 CKD patients (CKD stage G1 to G5 patients or on renal replacement therapy – CKD G5D) from Ghent University Hospital and 31 healthy controls. All-cause mortality and cardiovascular and renal events were registered as endpoints over a 6 year follow-up period. miR-126 levels were significantly lower from CKD stage G2 on, compared to controls. The serum levels of miR-223 were significantly lower from CKD stage G3B on. When considering overall mortality, patients with levels of either miR-126 or miR-223 below the median had a lower survival rate. Similar results were observed for CV and renal events. The observed link between the two miRNAs’ seric levels and mortality, cardiovascular events or renal events in CKD appears to depend on eGFR. However, this does not preclude their potential role in the pathophysiology of CKD. In conclusion, CKD is associated with a decrease in circulating miR-223 and miR-126 levels.

UR - http://www.scopus.com/inward/record.url?scp=85062959371&partnerID=8YFLogxK

U2 - 10.1038/s41598-019-41101-8

DO - 10.1038/s41598-019-41101-8

M3 - Article

C2 - 30872798

AN - SCOPUS:85062959371

SN - 2045-2322

VL - 9

JO - Scientific reports

JF - Scientific reports

IS - 1

M1 - 4477

ER -

Serum levels of miR-126 and miR-223 and outcomes in chronic kidney disease patients

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this